A single-step process for engineering hypoimmunogenic pluripotent stem cells with the Pin-point™ platform

Pluripotent stem cells (PSCs) hold great promise for the manufacturing of cell therapies. Off-the-shelf allogeneic products derived from PSCs engineered have the potential to dramatically broaden access to these therapies. However, their sensitivity to DNA damage presents challenges for efficiently performing the complex genome editing operations necessary to realise much of their potential.

Base editors represent a potential solution to these challenges due to their reduced genotoxicity compared to nuclease-based technologies.

In this poster, we demonstrate the power of the Pin-point™ base editing platform for the engineering of allogeneic PSCs.

The Pin-point platform technology is available for clinical study and commercialization under a commercial license from Revvity. Pin-point reagents are available for research use only.